BECN1 knockdown, in combination with BCL2+BCL-W co-inhibition, inhibited autophagy, restored ICI sensitivity, and increased apoptosis (but not necrosis) in ICI treated antiestrogen-resistant breast cancer cells. Here, BCL2L2 is linked to breast carcinoma.